Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus recommendation of “Hold” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $13.75.

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $9.88 on Monday. The stock has a market capitalization of $485.80 million, a price-to-earnings ratio of -9.78 and a beta of 0.23. The stock’s 50 day moving average price is $9.05 and its two-hundred day moving average price is $8.77. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The firm had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same quarter in the previous year, the firm posted ($0.17) EPS. On average, equities research analysts forecast that Theravance Biopharma will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TBPH. BNP Paribas Financial Markets increased its holdings in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 143,781 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Theravance Biopharma during the 2nd quarter worth approximately $986,000. Algert Global LLC acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth approximately $851,000. Finally, Bank of Montreal Can increased its holdings in shares of Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 93,702 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.